Oppenheimer Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)

By Jason Carr

In a report released yesterday, Leland Gershell from Oppenheimer maintained a Buy rating on Catalyst Pharma (CPRXResearch Report), with a price target of $10.00. The company’s shares closed last Wednesday at $4.16.

According to TipRanks.com, Gershell is a 3-star analyst with an average return of 0.6% and a 39.6% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

Catalyst Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.

See today’s analyst top recommended stocks >>

Catalyst Pharma’s market cap is currently $384.7M and has a P/E ratio of 13.50. The company has a Price to Book ratio of 4.63.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.